LSTM Home > LSTM Research > LSTM Online Archive

Drug-resistant tuberculosis treatments, the case for a phase III platform trial.

Yates, Tom A, Barnes, Samara, Dedicoat, Martin, Kon, Onn Min, Kunst, Heinke, Lipman, Marc, Millington, Kerry, Nunn, Andrew J, Phillips, Patrick Pj, Potter, Jessica L and Squire, Bertie ORCID: https://orcid.org/0000-0001-7173-9038 (2024) 'Drug-resistant tuberculosis treatments, the case for a phase III platform trial.'. Bulletin of the World Health Organization, Vol 102, Issue 9, pp. 657-664.

[img]
Preview
Text
BLT.23.290948.pdf
Available under License Creative Commons Attribution.

Download (960kB) | Preview

Abstract

Most phase III trials in drug-resistant tuberculosis have either been underpowered to quantify differences in microbiological endpoints or have taken up to a decade to complete. Composite primary endpoints, dominated by differences in treatment discontinuation and regimen changes, may mask important differences in treatment failure and relapse. Although new regimens for drug-resistant tuberculosis appear very effective, resistance to new drugs is emerging rapidly. There is a need for shorter, safer and more tolerable regimens, including those active against bedaquiline-resistant tuberculosis. Transitioning from multiple regimen A versus regimen B trials to a single large phase III platform trial would accelerate the acquisition of robust estimates of relative efficacy and safety. Further efficiencies could be achieved by adopting modern adaptive platform designs. Collaboration among trialists, affected community representatives, funders and regulators is essential for developing such a phase III platform trial for drug-resistant tuberculosis treatment regimens.

Item Type: Article
Subjects: QW Microbiology and Immunology > QW 45 Microbial drug resistance. General or not elsewhere classified.
WF Respiratory System > Tuberculosis > WF 200 Tuberculosis (General)
Faculty: Department: Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI): https://doi.org/10.2471/BLT.23.290948
SWORD Depositor: JISC Pubrouter
Depositing User: JISC Pubrouter
Date Deposited: 04 Oct 2024 12:26
Last Modified: 04 Oct 2024 12:26
URI: https://archive.lstmed.ac.uk/id/eprint/25348

Statistics

View details

Actions (login required)

Edit Item Edit Item